THE WORLD'S ONLY GOLD STANDARD VALIDATED TEST FOR IDENTIFYING & DISTINGUISHING ALZHEIMER'S DISEASE FROM OTHER FORMS OF DEMENTIA
KNOW THE FACTS*1.Alzheimer’s disease is the most common form of dementia and may contribute to 60–70% of cases.
2.More than 5 million Americans are living with Alzheimer’s. By 2050, this number is projected to rise to nearly 14 million.
3.There are more than 500k new cases every year in the US alone.
DIAGNOSIS WITHOUT A DOUBT
*Alzheimer's Associations®
1.
Alzheimer’s disease is the most common form of dementia and may contribute to 60–70% of cases.
2.
More than 5 million Americans are living with Alzheimer’s. By 2050, this number is projected to rise to nearly 14 million.
3.
There are more than 500k new cases every year in the US alone.
DIAGNOSIS WITHOUT A DOUBT
A DEFINITIVE DIAGNOSIS OF AD
DISCERN™ is the world’s first easy to administer test that can accurately identify Alzheimer’s Disease even at the earliest stages of onset by testing for the presence of 3 key proprietary biomarkers, unique to AD. It enables healthcare providers a definitive diagnosis of AD versus other forms of dementia and empowers them to enact a plan of care and a pathway to prepare for the future.
Easily administered, DISCERN™ requires a small skin sample taken by a certified healthcare provider. DISCERN™ is the only test that can provide clinicians a diagnosis with 95% certainty whether a patient has Alzheimer’s Disease or not.
Patients with a dementia diagnosis can use DISCERN™ to determine if they have Alzheimer’s Disease or not.
HOW DISCERN™ WORKS
DISCERN™ was designated a “breakthrough” device. It identifies 3 key biomarkers, which together can precisely identify Alzheimer’s Disease from other forms of dementia. The test requires a routine doctor’s visit, where a trained clinician takes a small skin sample using our pre-packaged, sterilized testing and shipping kit. The doctor securely ships the sample to our state-of-the-art testing facility. Our scientists will analyze for the presence of the 3 tell-tale DISCERN™ biomarkers. Patients and family members can have peace of mind when results have been determined.
THE PROCESS IS SIMPLE1.
A small skin sample is
taken by your doctor
2.
Your doctor ships
the test to our lab
3.
We then incubate and
evaluate the sample
1.
A small skin sample is
taken by your doctor
2.
Your doctor ships
the test to our lab
3.
We then incubate and
evaluate the sample
KNOW THE EARLY SIGNS & SYMPTOMSOF ALZHEIMER’S DISEASE*
- Does memory loss disrupt your daily life?
- Are you experiencing challenges in planning or solving problems?
- Do you have difficulty completing familiar tasks?
- Are you confused with time or place?
- Do you have trouble understanding visual images and spatial relationships?
- Are you experiencing new problems with words in speaking or writing?
- Do you misplace things and lose the ability to retrace steps?
- Do you experience decreased or poor judgment?
- Are you withdrawing from work or social activities?
- Do you have changes in mood and personality?
*Alzheimer's Associations®
- Does memory loss disrupt your daily life?
- Are you experiencing challenges in planning or solving problems?
- Do you have difficulty completing familiar tasks?
- Are you confused with time or place?
- Do you have trouble understanding visual images and spatial relationships?
- Are you experiencing new problems with words in speaking or writing?
- Do you misplace things and lose the ability to retrace steps?
- Do you experience decreased or poor judgment?
- Are you withdrawing from work or social activities?
- Do you have changes in mood and personality?
If you or someone you love is experiencing memory loss, NOW IS THE TIME to discuss DISCERN™ with your family physician. This test is minimally invasive, easy to administer and is cost-effective.
DISCERN™ establishes an accurate diagnosis, optimal treatment pathways, eliminating unnecessary medical tests and interventions.
Memory loss can be brought on by a myriad of medical issues, including Lyme’s Disease, vitamin deficiencies, thyroid issues, drug interactions and the various forms of dementia. Without enough facts, it’s frustrating, expensive and overwhelming to navigate through the journey often associated with various testing methods while not knowing how to plan for the future.
An early diagnosis saves time, money and the despair of not knowing for all who are involved. According to a recent report published in The British Medical Journal, “Early diagnosis gives patients the chance to have a say in their own care.”
PIONEERING LEADERSHIP IN THE FIELD OF AD
“DISCERN™ provides a minimally invasive means of identifying patients who have Alzheimer’s disease, even in the early years of the disease, when clinical diagnosis can be highly inaccurate.”
— DR. DANIEL ALKON
The 3 biomarkers were first identified and developed by a team of scientists led by Dr. Daniel Alkon after many years of extensive research at the Blanchette Rockefeller Neuroscience Institute. Dr. Alkon served as the Director of the Institute.
He spent 30 years conducting research in neuroscience and memory at the U.S. National Institutes of Health (NIH) as a Medical Director in the National Institute of Neurological Disorders and Stroke (NINDS) and as Chief of the Laboratory of Adaptive Systems. He has authored several books such as: “Memory traces in the brain” (Cambridge University press) and “Memory’s Voice” (Harper Collins).
TESTIMONIALS
As a doctor, I’ve always doubted answers from a standard questionnaire. Anyone can say anything and it’s up to us to discern accuracy based on the Gold standard, and to not rely on a standard questionnaire or a physical neurological exam as an accurate diagnosis of AD. Until Synaps DX Discern, there was no test I had confidence in using, but the Discern test biopsy had autopsy and skin post-mortem brain data to diagnose AD vs other dementias. With the greatest sensitivity and specificity (95%+) I am using this test to diagnose patients with confidence. MRIs, CT Scans and SF tests are aggressive, expensive and do not have the sensitivity and specificity needed to diagnose AD.
Magdalena Traudt, M.D.
Board Certified Family Physician
Early diagnosis harbors silver linings...opportunities to improve lifestyle habits and minimize drug side effects which affect cognition, in order to enhance our autonomy, functional independence and life experiences for as long as possible.
Michael Arambula, M.D., Pharm.D.
General & Forensic Psychiatry Clinical Pharmacology
The Discern Test helps me to cement the diagnosis of whether the patient truly has Alzheimer’s Disease or another form of Dementia. We utilize the Discern Test along with other diagnostic tools which can help detect AD years in advance & therefore make necessary changes today to positively impact the patients future.
Divya Javvaji, M.D.
Geriatrician Internist
PROVEN TECHNOLOGY
Backed by decades of clinical research, the novel DISCERN™ biomarkers have been validated in human clinical trials. These studies were conducted at the Blanchette Rockefeller Neuroscience Institute and were determined to be extremely accurate in both detecting Alzheimer’s Disease and differentiating AD from other dementias.
WHEN YOU ARE SEARCHING FOR ANSWERS, DISCERN™ PROVIDES RESULTS YOU CAN TRUST.
